Drugs Nivolumab

Phase 2Monoclonal antibody

Drugs Nivolumab is one of 8 small molecule programs targeting Allogeneic Stem Cell Transplantation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allogeneic Stem Cell TransplantationRecruiting

Allogeneic Stem Cell TransplantationPhase 2

Recruiting

Competition

Competitive Landscape

8 competitors in Allogeneic Stem Cell Transplantation

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

12 2

Cellcept

Roche

Phase 3

2 3

Tepadina

Jazz Pharmaceuticals

Phase 3

2 4

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 5

Jakafi

Incyte

Phase 2

1 6

Prograf

VVeloxis Pharmaceuticals

Phase 2

3 7

Desferal

Jazz Pharmaceuticals

Preclinical

1 8

Drugs Nivolumab

MM.D. Anderson Cancer Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Active, not recruiting

Renal Cell Carcinoma, Clear Cell

NCT06708949

Q4 2029

Phase 2Recruiting

Allogeneic Stem Cell Transplantation

NCT06807606

Clinical

Trials by Indication[1]

Allogeneic Stem Cell Transplantation1 trial

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06807606·35 enrolled

Renal Cell Carcinoma, Clear Cell1 trial

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06708949·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Drugs Nivolumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drugs Nivolumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drugs Nivolumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

Drugs Nivolumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q4 2029

Trials by Indication[1]

Allogeneic Stem Cell Transplantation1 trial

Renal Cell Carcinoma, Clear Cell1 trial

References

Drug Info

Quick Facts

Related News